
Dr Mario Castro explains how type 2 cytokines play a crucial role in airway remodeling and inflammation in asthma and COPD, impacting patient outcomes.

Join Dr. Hanania to understand how to identify patients at risk of fixed airway obstruction in clinical settings.
See how type 2 inflammation underlies remodeling processes in asthma.

Join experts Mario Castro, Nicola Hanania, and Stephanie Christenson for an educational symposium on the real-world impact of underlying type 2 inflammation on the patient burden of asthma and COPD.

In this video soundbite from the EAACI 2025 symposium, Dr. Zuzana Diamant explains pathophysiological mechanisms underlying asthma and CRSwNP, and how type 2 inflammatory cytokines drive airway remodelling in patients with severe asthma. Additionally, patients with co-existing asthma and CRSwNP have a higher type 2 inflammatory burden than patients with asthma alone.
Learn about the significant burden that patients with COPD experience and the role of inflammatory mechanisms in this chronic, often progressive disease.